Drug delivery systems for RNA therapeutics
Reads0
Chats0
TLDR
A review of RNA therapeutic classes, their molecular mechanisms of action, and the design considerations for their respective delivery platforms can be found in this paper , where the authors discuss the path from preclinical drug delivery research to clinical approval of these drugs.Abstract:
RNA-based gene therapy requires therapeutic RNA to function inside target cells without eliciting unwanted immune responses. RNA can be ferried into cells using non-viral drug delivery systems, which circumvent the limitations of viral delivery vectors. Here, we review the growing number of RNA therapeutic classes, their molecular mechanisms of action, and the design considerations for their respective delivery platforms. We describe polymer-based, lipid-based, and conjugate-based drug delivery systems, differentiating between those that passively and those that actively target specific cell types. Finally, we describe the path from preclinical drug delivery research to clinical approval, highlighting opportunities to improve the efficiency with which new drug delivery systems are discovered. RNA therapies can be used to manipulate gene expression or produce therapeutic proteins. Here, the authors describe the growing number of RNA therapies and their molecular mechanisms of action. They also discuss the path from preclinical drug delivery research to clinical approval of these drugs. read more
Citations
More filters
Journal ArticleDOI
Therapeutic in vivo delivery of gene editing agents
TL;DR: In this article , the authors compared the benefits and drawbacks of different delivery modalities and highlighted opportunities for future improvements, since no single delivery modality is likely to be appropriate for every possible application.
Journal ArticleDOI
The landscape of mRNA nanomedicine
TL;DR: The recent success of the two highly efficacious mRNA vaccines produced by Moderna and Pfizer-BioNTech to protect against COVID-19 highlights the huge potential of mRNA technology for revolutionizing life science and medical research as mentioned in this paper .
Journal ArticleDOI
Chemical and Biophysical Signatures of the Protein Corona in Nanomedicine.
Jiayu Ren,Nicholas Andrikopoulos,Kelly Velonia,Huayuan Tang,Rong Cai,F. Ding,Pu Chun Ke,Chunying Chen +7 more
TL;DR: The chemical and biophysical signatures of the protein corona are discussed and challenges ahead for the field of nanomedicine are pondered.
Journal ArticleDOI
Augmented lipid-nanoparticle-mediated in vivo genome editing in the lungs and spleen by disrupting Cas9 activity in the liver
Cory D. Sago,Melissa P. Lokugamage,David Loughrey,Kevin E. Lindsay,Robert Hincapie,Brandon R. Krupczak,Sujay Kalathoor,Manaka Sato,Elisa Schrader Echeverri,Jordan P. Fitzgerald,Zubao Gan,Lena Gamboa,Kalina Paunovska,Carlos A. Sanhueza,Marine Z. C. Hatit,M. G. Finn,Philip J. Santangelo,James E. Dahlman +17 more
TL;DR:
Journal ArticleDOI
Long Non-Coding RNA and RNA-Binding Protein Interactions in Cancer: Experimental and Machine Learning Approaches.
Hibah Shaath,Radhakrishnan Vishnubalaji,Ramesh Elango,A. Kardousha,Zeyaul Islam,Rizwan Qureshi,Tanvir Alam,Prasanna R. Kolatkar,Nehad M. Alajez +8 more
TL;DR: In this paper , the reciprocal interplay between lncRNAs and RBPs and their involvement in epigenetic regulation via histone modifications, as well as their key role in resistance to cancer therapy are discussed.
References
More filters
Journal ArticleDOI
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans
Andrew Fire,SiQun Xu,Mary K. Montgomery,Steven A. Kostas,Steven A. Kostas,Samuel E. Driver,Craig C. Mello +6 more
TL;DR: To their surprise, it was found that double-stranded RNA was substantially more effective at producing interference than was either strand individually, arguing against stochiometric interference with endogenous mRNA and suggesting that there could be a catalytic or amplification component in the interference process.
Journal ArticleDOI
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Fernando P. Polack,Stephen J. Thomas,Nicholas Kitchin,Judith Absalon,Alejandra Gurtman,Stephen Lockhart,John L. Perez,Gonzalo Pérez Marc,Edson D. Moreira,Cristiano Zerbini,Ruth Bailey,Kena A. Swanson,Satrajit Roychoudhury,Kenneth Koury,Ping Li,Warren Kalina,David A. Cooper,Robert W. Frenck,Laura L. Hammitt,Özlem Türeci,Haylene Nell,Axel Schaefer,Serhat Ünal,Dina B. Tresnan,Susan Mather,Philip R. Dormitzer,Ugur Sahin,Kathrin U. Jansen,William C. Gruber +28 more
TL;DR: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older and safety over a median of 2 months was similar to that of other viral vaccines.
Journal ArticleDOI
Understanding biophysicochemical interactions at the nano–bio interface
Andre E. Nel,Lutz Mädler,Darrell Velegol,Tian Xia,Eric M.V. Hoek,Ponisseril Somasundaran,Fred Klaessig,Vince Castranova,Mike Thompson +8 more
TL;DR: Probing the various interfaces of nanoparticle/biological interfaces allows the development of predictive relationships between structure and activity that are determined by nanomaterial properties such as size, shape, surface chemistry, roughness and surface coatings.
Journal ArticleDOI
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine,Robert P. Giugliano,Anthony C Keech,Narimon Honarpour,Stephen D. Wiviott,Sabina A. Murphy,Sabina A. Murphy,Julia F Kuder,Julia F Kuder,Huei Wang,Thomas Liu,Scott M. Wasserman,Peter S. Sever,Terje R. Pedersen,Terje R. Pedersen +14 more
TL;DR: In this trial, inhibition of PCSK9 with evolocumab on a background of statin therapy lowered LDL cholesterol levels to a median of 30 mg per deciliter (0.78 mmol per liter) and reduced the risk of cardiovascular events.
Journal ArticleDOI
Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system.
Bernd Zetsche,Jonathan S. Gootenberg,Omar O. Abudayyeh,Ian Slaymaker,Kira S. Makarova,Patrick Essletzbichler,Sara E. Volz,Julia Joung,John van der Oost,Aviv Regev,Aviv Regev,Eugene V. Koonin,Feng Zhang +12 more
TL;DR: In this paper, the authors characterized Cpf1, a putative class 2 CRISPR effector, which is a single RNA-guided endonuclease lacking tracrRNA and utilizes a T-rich protospacer-adjacent motif.